Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Lewy Body Disease 1Congenital Hyperinsulinism 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 23Radiosurgery 21Temozolomide 14Bevacizumab 11pembrolizumab 10Specimen Handling 9Nivolumab 8Radiotherapy 7Ipilimumab 7Magnetic Resonance Imaging 6Cyclophosphamide 5Capecitabine 5Blood Specimen Collection 5encorafenib 4Radiation 4Neuropsychological Tests 4Mental Status and Dementia Tests 4Memantine 4Carboplatin 4fludarabine 3fluciclovine F-18 3binimetinib 3abemaciclib 3Watchful Waiting 3Proton Therapy 3Etoposide 3Dexamethasone 3Adrenal Cortex Hormones 3trastuzumab deruxtecan 2sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Brain Neoplasms × Furosemide × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡